Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Nutrition Facts Update, Valeant Sales

This article was originally published in The Tan Sheet

Executive Summary

FDA to update Nutrition and Supplement Facts labels; Valeant over performs in Q4, 2013; “probiotic” alone is a health claim, ASA; Troxyphen claims need modification, ERSP; and more In Brief.

You may also be interested in...



Additional Sugar Label Requirements Taste Sour To Supplement Industry

FDA proposes revisions to a 2014 proposed rule due to the 2015 Dietary Guideline Advisory Committee’s report. In a supplemental proposed rule, FDA will establish a daily reference value of 10% of total energy intake from added sugars and require label declarations of the percent daily value for added sugars.

Additional Sugar Label Requirements Taste Sour To Supplement Industry

FDA proposes revisions to a 2014 proposed rule due to the 2015 Dietary Guideline Advisory Committee’s report. In a supplemental proposed rule, FDA will establish a daily reference value of 10% of total energy intake from added sugars and require label declarations of the percent daily value for added sugars.

Androfen Calculations Off Target For Reasonable Interpretations Of Claim – ERSP

Androfen should discontinue claims its testosterone-boosting supplement can “reduce body fat by over 200%” because consumers can interpret it in a way that is not supported, ERSP says. The firm can continue to claim the fenugreek product enhances libido and promotes body fat loss.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel